Evidence map›Paper›PMID 38058193›Full record

ArticleBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia2025

Clinical and molecular genetic analysis of cytologically uncertain thyroid nodules in patients with thyroid disease.

Jindrich Lukas, Barbora Hintnausova, Vlasta Sykorova, Martin Syrucek, Marek Maly, David Lukas, Jaroslava Duskova

Open access · goldAbstract read
PubMed Publisher
In one paragraph

Article in Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 67% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jindrich LukasDepartment of Otolaryngology - Head and Neck Surgery, Na Homolce Hospital, Prague, Czech Republic.
Barbora HintnausovaDepartment of Internal Medicine, Endocrinology Centre, Na Homolce Hospital, Prague, Czech Republic.
Vlasta SykorovaInstitute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic.
Martin SyrucekDepartment of Pathology, Na Homolce Hospital, Prague, Czech Republic.
Marek MalyDepartment of Biostatistics, National Institute of Public Health, Prague, Czech Republic.
David LukasDepartment of General Surgery, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Jaroslava DuskovaInstitute of Pathology, 1st Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Charles University · CZInstitute of Endocrinology · CZNa Homolce Hospital · CZNational Institute of Public Health · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current requirement is to establish the preoperative diagnosis accurately as possible and to achieve an adequate extent of surgery. The aim of this study was to define the preoperative clinical and molecular genetic risks of malignancy in indeterminate thyroid nodules (Bethesda III and IV) and to determine their impact on the surgical strategy.

methodsProspectively retrospective analysis of 287 patients provided the basis of preoperative laboratory examination, sonographic stratification of malignancy risks and cytological findings. Molecular tests focused on pathogenic variants of genes associated with thyroid oncogenesis in cytologically indeterminate nodules (Bethesda III and IV). The evaluation included clinical risk factors: positive family history, radiation exposure and growth in size and/or number of nodules.

resultsPreoperative FNAB detected 52 cytologically indeterminate nodules (28.7%) out of 181 patients. Postoperative histopathological examination revealed malignancy in 12 cases (23.7%) and there was no significant difference between Bethesda III and IV categories (P=0.517). Clinical risk factors for malignancy were found in 32 patients (61.5%) and the presence of at least one of them resulted in a clearly higher incidence of malignancy than their absence (31.3% vs. 10.0%, respectively). Pathogenic variants of genes were detected in 12/49 patients in Bethesda III and IV, and in 4 cases (33.3%) thyroid carcinoma was revealed. The rate of malignancies was substantially higher in patients with pathogenic variants than in those without (33.3% vs. 16.2%, respectively).

conclusionsOur experience implies that molecular genetic testing is one of several decision factors. We will continue to monitor and enlarge our patient cohort to obtain long-term follow-up data.

Indexed as

Thyroid NeoplasmsThyroid NoduleAdultAgedBiopsy, Fine-NeedleFemaleHumansMaleMiddle AgedProspective StudiesRetrospective StudiesRisk FactorsYoung Adultcytologymolecular testingthyroidectomythyroid nodules

Identifiers

PMID38058193
OpenAlexW4389451760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.